Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 854.74M | P/E | - | EPS this Y | -1.40% | Ern Qtrly Grth | - |
| Income | -56.54M | Forward P/E | -16.72 | EPS next Y | 10.30% | 50D Avg Chg | -23.00% |
| Sales | 191.43M | PEG | -11.77 | EPS past 5Y | - | 200D Avg Chg | -48.00% |
| Dividend | N/A | Price/Book | 5.50 | EPS next 5Y | 1.60% | 52W High Chg | -62.00% |
| Recommedations | 3.30 | Quick Ratio | 6.28 | Shares Outstanding | 40.63M | 52W Low Chg | 12.00% |
| Insider Own | 4.15% | ROA | -14.11% | Shares Float | 37.63M | Beta | 1.54 |
| Inst Own | 97.46% | ROE | -36.45% | Shares Shorted/Prior | 3.15M/2.57M | Price | 22.07 |
| Gross Margin | 74.28% | Profit Margin | -29.53% | Avg. Volume | 935,798 | Target Price | 20.75 |
| Oper. Margin | -33.56% | Earnings Date | Nov 6 | Volume | 1,457,113 | Change | -3.67% |
About Silk Road Medical, Inc.
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California. As of September 17, 2024, Silk Road Medical, Inc operates as a subsidiary of Boston Scientific Corporation.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Jones Marie L. | CAO and VP, Finance CAO and VP, Finance | Oct 27 | Sell | 6.607 | 656 | 4,334 | 54,941 | 10/30/23 |
| Buchanan Lucas W. | COO/CFO COO/CFO | Oct 04 | Sell | 15.223 | 2,662 | 40,524 | 435,848 | 10/06/23 |
| Rogers Erica J. | President and CEO President and CEO | Mar 02 | Sell | 56.6189 | 1,651 | 93,478 | 267,988 | 09/29/23 |
| Klemz Kevin M | EVP/Chief Legal Offi.. EVP/Chief Legal Officer/Sec. | Aug 17 | Sell | 20.105 | 1,539 | 30,942 | 38,797 | 08/18/23 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | May 19 | Sell | 22.13 | 6,587 | 145,770 | 109,534 | 08/04/23 |
| Buchanan Lucas W. | COO/CFO COO/CFO | May 19 | Option | 10.8 | 9,643 | 104,144 | 215,725 | 07/31/23 |
| Jones Marie L. | CAO and VP, Finance CAO and VP, Finance | May 19 | Option | 6.11 | 2,000 | 12,220 | 48,002 | 07/21/23 |
| Rogers Erica J. | President and CEO President and CEO | Jul 11 | Sell | 31.56 | 1,000 | 31,560 | 269,639 | 07/13/23 |
| Rogers Erica J. | President and CEO President and CEO | Jul 11 | Option | 1.6 | 1,000 | 1,600 | 270,639 | 07/13/23 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | Jul 06 | Sell | 30.787 | 69 | 2,124 | 115,614 | 07/10/23 |
| Rogers Erica J. | President and CEO President and CEO | May 19 | Sell | 32.13 | 1,000 | 32,130 | 269,639 | 06/13/23 |
| Rogers Erica J. | President and CEO President and CEO | May 19 | Option | 1.6 | 1,000 | 1,600 | 270,639 | 06/13/23 |
| Rogers Erica J. | President and CEO President and CEO | May 11 | Sell | 35.51 | 3,000 | 106,530 | 269,132 | 05/12/23 |
| Rogers Erica J. | President and CEO President and CEO | May 11 | Option | 1.6 | 3,000 | 4,800 | 272,132 | 05/12/23 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | May 01 | Sell | 44.51 | 6,753 | 300,576 | 115,683 | 05/03/23 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | May 01 | Option | 8.89 | 6,753 | 60,034 | 122,436 | 05/03/23 |
| WEATHERMAN ELIZABETH H | Director Director | Apr 17 | Sell | 41.91 | 5,000 | 209,550 | 144,454 | 04/19/23 |
| Rogers Erica J. | President and CEO President and CEO | Apr 11 | Sell | 39.77 | 6,000 | 238,620 | 269,132 | 04/12/23 |
| Rogers Erica J. | President and CEO President and CEO | Apr 11 | Option | 1.6 | 6,000 | 9,600 | 275,132 | 04/12/23 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | Apr 03 | Sell | 39.42 | 6,753 | 266,203 | 115,683 | 04/05/23 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | Apr 03 | Option | 5.19 | 6,753 | 35,048 | 122,436 | 04/05/23 |
| WEATHERMAN ELIZABETH H | Director Director | Mar 15 | Sell | 41.91 | 5,000 | 209,550 | 149,454 | 03/17/23 |
| Rogers Erica J. | President and CEO President and CEO | Mar 13 | Sell | 42.23 | 6,000 | 253,380 | 269,132 | 03/15/23 |
| Rogers Erica J. | President and CEO President and CEO | Mar 13 | Option | 1.6 | 6,000 | 9,600 | 275,132 | 03/15/23 |
| Ruedy Richard | EVPClin&Reg.Affa.. EVPClin&Reg.Affairs&QA | Mar 02 | Sell | 47.73 | 2,373 | 113,263 | 145,483 | 03/06/23 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | Mar 02 | Sell | 47.74 | 3,868 | 184,658 | 115,683 | 03/06/23 |
| Buchanan Lucas W. | COO/CFO COO/CFO | Mar 02 | Sell | 47.11 | 9,918 | 467,237 | 205,575 | 03/06/23 |
| Rogers Erica J. | President and CEO President and CEO | Mar 02 | Sell | 47.1 | 18,043 | 849,825 | 269,132 | 03/06/23 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | Mar 01 | Sell | 48.02 | 6,753 | 324,279 | 98,205 | 03/02/23 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | Mar 01 | Option | 4.73 | 6,753 | 31,942 | 99,019 | 03/02/23 |
| WEATHERMAN ELIZABETH H | Director Director | Feb 15 | Sell | 49.86 | 5,000 | 249,300 | 154,454 | 02/17/23 |
| Rogers Erica J. | President and CEO President and CEO | Feb 13 | Sell | 50.94 | 6,000 | 305,640 | 246,199 | 02/15/23 |
| Rogers Erica J. | President and CEO President and CEO | Feb 13 | Option | 1.6 | 6,000 | 9,600 | 252,199 | 02/15/23 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | Feb 01 | Sell | 54.05 | 6,753 | 365,000 | 98,205 | 02/03/23 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | Feb 01 | Option | 4.73 | 6,753 | 31,942 | 104,958 | 02/03/23 |
| Chou Tony M. | Director Director | Feb 01 | Sell | 55 | 13,008 | 715,440 | 75,707 | 02/03/23 |
| Buchanan Lucas W. | COO/CFO COO/CFO | Jan 17 | Sell | 53.72 | 86,244 | 4,633,028 | 188,811 | 01/19/23 |
| Buchanan Lucas W. | COO/CFO COO/CFO | Jan 17 | Option | 7.73 | 83,528 | 645,671 | 217,289 | 01/19/23 |
| WEATHERMAN ELIZABETH H | Director Director | Jan 17 | Sell | 54.693 | 56,355 | 3,082,224 | 159,454 | 01/19/23 |
| Chou Tony M. | Director Director | Jan 12 | Sell | 55 | 1,006 | 55,330 | 87,709 | 01/17/23 |
| Rogers Erica J. | President and CEO President and CEO | Jan 11 | Sell | 51.53 | 6,000 | 309,180 | 246,199 | 01/13/23 |
| Rogers Erica J. | President and CEO President and CEO | Jan 11 | Option | 1.6 | 6,000 | 9,600 | 252,199 | 01/13/23 |
| Buchanan Lucas W. | COO/CFO COO/CFO | Dec 13 | Option | 1.6 | 40,000 | 64,000 | 191,527 | 12/15/22 |
| Buchanan Lucas W. | COO/CFO COO/CFO | Dec 13 | Sell | 55 | 25,000 | 1,375,000 | 176,527 | 12/15/22 |
| Chou Tony M. | Director Director | Dec 13 | Sell | 55 | 10,060 | 553,300 | 88,715 | 12/15/22 |
| Rogers Erica J. | President and CEO President and CEO | Dec 12 | Option | 1.6 | 10,000 | 16,000 | 256,199 | 12/14/22 |
| Rogers Erica J. | President and CEO President and CEO | Dec 12 | Sell | 53.85 | 10,000 | 538,500 | 246,199 | 12/14/22 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | Nov 01 | Option | 1.46 | 6,753 | 9,859 | 104,958 | 11/01/22 |
| Davis Andrew S. | Chief Commercial Off.. Chief Commercial Officer | Nov 01 | Sell | 44.17 | 6,753 | 298,280 | 98,205 | 11/01/22 |
| Rogers Erica J. | President and CEO President and CEO | Sep 12 | Option | 1.6 | 10,000 | 16,000 | 256,199 | 09/14/22 |